Compounds and methods for kinase modulation, and indications therefor

Patent metadata

Field	Value
Publication number	US-2025195516-A1
Application number	US-202418778765-A
Country	US
Kind code	A1
Filing date	Jul 19, 2024
Priority date	Feb 7, 2011
Publication date	Jun 19, 2025
Grant date	—

Abstract

Compounds active on protein kinases are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.

First claim

1 . A compound of formula I:

or pharmaceutically acceptable salts, hydrates, solvates, tautomers and isomers, thereof; wherein:
Y 1 is selected from the group consisting of CN, halogen, —OH, optionally substituted C 1-6 alkyl, optionally substituted C 1-6 alkoxy, optionally substituted C 3-6 cycloalkyl, optionally substituted C 1-6 haloalkyl, optionally substituted C 1-6 haloalkoxy, optionally substituted aryl and optionally substituted heteroaryl; optionally wherein the two adjacent substituents on the aryl or heteroaryl ring together with the atoms to which they are attached form an optionally substituted 5- or 6-membered ring having from 0 to 3 additional heteroatoms selected from N, O or S;
Y 2 is H, halogen, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, aryl, arylalkyl, heteroaryl, heteroarylalkyl, C 3-8 cycloalkyl-C 0-4 alkyl or (R 2 )(R 3 )N—, wherein R 2 and R 3 are each independently selected from the group consisting of H, C 1-6 alkyl, C 1-6 alkoxy, aryl, arylalkyl, heteroaryl, heteroarylalkyl, C 3-8 cycloalkyl-C 0-4 alkyl, heterocycloalkyl and heterocycloalkyl-C 1-4 alkyl; or R 2 and R 3 taken together with the nitrogen atom to which they are attached form a three to eight-membered ring having from 0-2 additional heteroatoms as ring members selected from N, O or S; wherein Y 2 is optionally substituted with from one to three groups independently selected from R e ;
Q is selected from H, F, Cl or CH 3 ;
Z is —N(R 4 )(R 5 ) or —C(R 6 )(R 7 )(R 8 ), wherein
R 4 and R 5 are each independently selected from the group consisting of H, optionally substituted C 1-6 alkyl, optionally substituted C 3-8 cycloalkyl, optionally substituted C 3-8 cycloalkylalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl; or
R 4 and R 5 taken together with the nitrogen atom to which they are attached form a four to eight-membered ring having from 0-2 additional heteroatoms as ring members selected from N, O or S, wherein the four to eight-membered ring is optionally substituted;
R 6 , R 7 and R 8 are each independently H, optionally substituted C 1-6 alkyl, optionally substituted, C 1-6 haloalkyl, optionally substituted C 1-6 haloalkoxy, optionally substituted C 3-8 cycloalkyl, optionally substituted C 3-8 cycloalkylalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl or —X 2 R 9 , wherein X 2 is —NR 10 , O or S; R 10 is H, C 1-6 alkyl or aryl; and R 9 is H, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 haloalkoxy, C 3-8 cycloalkyl, C 3-8 cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl, wherein R 9 is optionally substituted with from 1 to 3 R e substituents; or any two of the R 6 , R 7 and R 8 groups taken together with the carbon atom to which they are attached form a 3 to 8-membered optionally substituted non-aromatic ring having from 0 to 2 heteroatoms selected from N, O or S; provided at each occurrence, at least two of the R 6 , R 7 and R 8 groups are not simultaneously hydrogen; and
with the proviso when (i) Y 1 is halogen, —CH 3 , —CN, —OMe or 2-methoxypyrimidin-5-yl, Z is other than dimethylamino, diethylamino, 1-pyrrolidine, 1-piperidinyl, 4-morpholinyl, isopropyl, —CH(CH 3 )(CH 2 CH 3 ), —CH(CH 3 )(CH 2 CH 2 CH 3 ), cyclobutyl, cyclopentyl or cyclohexyl; and (ii) when Y 1 is 1-methyl-4-pyrazolyl, 3-methylsulfonylphenyl or 3-methylsulfonylaminophenyl, Z is other than cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.

2 .- 55 . (canceled)

Assignees

• Plexxikon Inc

Inventors

• Ibrahim Prabha N
• Zhang Chao
• Spevak Wayne
• Zhang Jiazhong
• Wu Guoxian
• Lin Jack
• Cho Hanna
• Nespi Marika
• Shi Songyuan
• Ewing Todd
• Zhang Ying

Classifications

• A61K31/5377

  not condensed and containing further heterocyclic rings, e.g. timolol · CPC title

• A61K31/437

  the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline · CPC title

• C07D471/04 Primary

  Ortho-condensed systems · CPC title

• C07D487/04

  Ortho-condensed systems · CPC title

• A61K31/407

  condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine · CPC title